Search company, investor...

Stage

Loan | Alive

Total Raised

$7.86M

Last Raised

$250K | 4 yrs ago

About Mobius Therapeutics

Mobius Therapeutics is a company focused on perioperative pharmaceuticals within the ophthalmology sector. They offer a range of pharmaceutical products designed to improve patient care, access, and provider safety during the perioperative period of eye surgeries. The company primarily serves healthcare providers and patients in the field of ophthalmology. It is based in St. Louis, Missouri.

Headquarters Location

4041 Forest Park Avenue

St. Louis, Missouri, 63108,

United States

314-615-6930

Loading...

Loading...

Mobius Therapeutics Patents

Mobius Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • dosage forms
  • drug delivery devices
  • eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/25/2022

1/3/2023

Eye surgery, Dosage forms, Ophthalmology, Medical equipment, Drug delivery devices

Grant

Application Date

3/25/2022

Grant Date

1/3/2023

Title

Related Topics

Eye surgery, Dosage forms, Ophthalmology, Medical equipment, Drug delivery devices

Status

Grant

Latest Mobius Therapeutics News

Mobius Therapeutics™ to Sponsor Educational Events on Compliance with USP <800>

May 15, 2023

News provided by Share this article Impending standards to impose new SOP's, storage, transport, use and training requirements ST. LOUIS, May 15, 2023 /PRNewswire/ -- Mobius Therapeutics™, LLC , a St. Louis-based perioperative ophthalmic pharmaceutical company, will initiate a series of professional education sessions, focused on how end users of Mitosol® can achieve compliance with USP <800> , the soon to be implemented and enforced standards for control of hazardous drugs in healthcare facilities. Mitosol (mitomycin for solution) Kit for Ophthalmic Use (PRNewsfoto/Mobius Therapeutics, LLC) "Since 2019, Mobius™ has assigned significant resources to facilitate the compliance process, to include exclusive learning modules , in-service support, and continuous web-based events," said Ed Timm, CEO of Mobius Therapeutics. "With an implementation date of November 1, 2023, we are aware of significant remaining gaps in basic knowledge of the standards. Cumulative in nature, these web events will begin at the most basic, introductory level, proceeding to the standards themselves, and concluding with what the end user must do to achieve compliance." Effective November 1, 2023, USP <800> is a new compulsory standard for sites using NIOSH designated hazardous drugs in healthcare settings. Mitosol® , the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication, facilitates compliance, without imposing burdensome transport, storage, and ventilation requirements. "Knowledge is power," continued Timm. "By educating end users, we improve the occupational safety of all healthcare workers. Our efforts in this regard help employees and patients, while reducing the burden and expense of achieving compliance. In the end, everyone wins: the patient, the providers, and the American healthcare system." About Mobius Therapeutics, LLC: Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals. Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use , is the only formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline. Please see full prescribing information at https://mitosol.com/mitosol-package-insert/ . CONTACT:

Mobius Therapeutics Frequently Asked Questions (FAQ)

  • Where is Mobius Therapeutics's headquarters?

    Mobius Therapeutics's headquarters is located at 4041 Forest Park Avenue, St. Louis.

  • What is Mobius Therapeutics's latest funding round?

    Mobius Therapeutics's latest funding round is Loan.

  • How much did Mobius Therapeutics raise?

    Mobius Therapeutics raised a total of $7.86M.

  • Who are the investors of Mobius Therapeutics?

    Investors of Mobius Therapeutics include Paycheck Protection Program, Cultivation Capital, Qualifying Therapeutic Discovery Project and St. Louis Enterprise Center West County.

  • Who are Mobius Therapeutics's competitors?

    Competitors of Mobius Therapeutics include Intrinsic Therapeutics, iTind, PulmonX, Cagenix, AirXpanders and 7 more.

Loading...

Compare Mobius Therapeutics to Competitors

N
NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops implantable bioelectronic therapies to treat chronic inflammatory diseases.. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. It was formerly known as Innovative Metabolics. The company was founded in 2007 and is based in Valencia, California.

Embolx Logo
Embolx

Embolx is a medical device company that focuses on the development of microcatheters for arterial embolization procedures. The company's main products are devices that aid in the treatment of various conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids by controlling blood flow and protecting non-target tissues. It was founded in 2013 and is based in Sunnyvale, California. Embolx operates as a subsidiary of Edwards Lifesciences.

P
Portaero

Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).

C
C2C

C2C specializes in the contract manufacturing of medical devices, offering comprehensive services from product development to commercialization. The company provides expertise in design, prototyping, regulatory strategy, and pilot production, as well as manufacturing, packaging, labeling, and sterilization of medical devices. C2C primarily serves the medical device industry, catering to inventors and companies seeking to bring new products to market or scale existing ones. It is based in Melbourne, Florida.

I
Intrinsic Therapeutics

Intrinsic Therapeutics develops medical devices. It offers a device to close large defects in the annulus and therapies for soft-tissue injuries of the spine. Intrinsic Therapeutics was formerly known as MedGenesis. The company was founded in 2000 and is based in Woburn, Massachusetts.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.